With more than $600 million on the line, AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics to advance three gene therapy programs for eye diseases.
https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceAbbVie.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-02-23 09:04:522023-02-23 09:04:52AbbVie, Capsida set sights on gene therapies for eye diseases
